Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.

Denosumab therapy effectively decreases the number of osteoclastic cells in GCTBs. However, the neoplastic cells with H3F3A mutation survive denosumab treatment and undergo dramatic histological changes in response to this agent.